Leaflet RECOMBINATE 250UI / 10ml powder+solvent for injection
Indicated for: bleeding; coagulation disorders
Route of administration: injectable
Substance: octocog alfa (anticoagulant)
ATC: B02BD02 (Blood and blood forming organs | Vitamin k and other hemostatics | Blood coagulation factors)
Dose adjustment may be needed in kidney disease.
This medicine may have important interactions with other medicines.
This medicine is subject to additional monitoring.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
This medicine may increase the risk of bleeding.
Octocog alfa is a recombinant factor VIII used for the treatment and prevention of bleeding episodes in patients with hemophilia A. It replaces the missing or deficient factor VIII, which is essential for blood clotting.
The medication is administered intravenously, as directed by your doctor, usually during bleeding episodes or prophylactically to prevent bleeds. It is important to follow the recommended treatment regimen.
Side effects may include injection site reactions, fever, headache, or, in rare cases, severe allergic reactions.
Patients should inform their doctor about any other medications being used or pre-existing conditions to ensure the safe use of octocog alfa.
General data about RECOMBINATE 250UI / 10ml
- Substance: octocog alfa
- Date of last drug list: 01-03-2017
- Commercial code: W63303001
- Concentration: 250UI / 10ml
- Pharmaceutical form: powder+solvent for injection
- Quantity: 1
- Product type: original
- Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Pharmaceutical forms available for octocog alfa
Concentrations available for octocog alfa
- 1000UI
- 1000UI/10ml
- 1000UI/2ml
- 1000UI/5ml
- 1500UI
- 1500UI/2ml
- 1500UI/5ml
- 2000UI
- 2000UI/5ml
- 250UI
- 250UI/10ml
- 250UI/2ml
- 250UI/5ml
- 3000UI
- 3000UI/5ml
- 500UI
- 500UI/10ml
- 500UI/2ml
- 500UI/5ml